Intuitive Surgical (ISRG) Earnings Date & Reports

Key Takeaways

• Q2 2026 revenue reached $2.89 billion, up 19% year over year and above consensus estimates.
• Non-GAAP diluted EPS of $2.80 beat analyst expectations by approximately $0.32 to $0.39.
• Worldwide da Vinci and Ion procedures grew about 16% year over year.
• 468 da Vinci systems placed, including 246 da Vinci 5 systems, expanding the installed base to 11,710.
• Full-year 2026 guidance reaffirmed with da Vinci procedure growth expected at 13.5% to 15.5%.
• GAAP net income rose to $818 million, or $2.29 per diluted share.

Earnings Context and Why It Matters

Intuitive Surgical’s quarterly results provide key insights into demand for its robotic-assisted surgical systems and related instruments. Strong procedure volume growth signals continued adoption of minimally invasive techniques across hospitals worldwide. The report also highlights system placements, leasing trends, and margin performance, which influence investor views on the company’s long-term growth trajectory in the medical device sector.

Reported Results

Intuitive Surgical reported second-quarter 2026 revenue of $2.89 billion, a 19% increase from $2.44 billion in the same quarter of 2025. Instruments and accessories revenue rose 18% to $1.73 billion, while systems revenue increased to $685 million. Non-GAAP net income attributable to the company reached $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, a year earlier. GAAP net income was $818 million, or $2.29 per diluted share. Both revenue and non-GAAP EPS exceeded consensus estimates. Worldwide procedures grew approximately 16%, with da Vinci procedures up about 15% and Ion procedures up 36%. The company placed 468 da Vinci systems and 55 Ion systems during the quarter.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore opportunities across sectors.

Market Reaction and Investor Sentiment

Shares of Intuitive Surgical typically move on earnings beats driven by procedure growth and system placements. The strong Q2 results, including revenue and earnings outperformance, reinforced positive sentiment heading into the report. Investors focused on the company’s ability to sustain momentum amid broader healthcare spending trends and adoption of robotic surgery.

Forward Outlook and Key Factors to Monitor

Intuitive Surgical reaffirmed its 2026 full-year outlook, expecting worldwide da Vinci procedure growth of 13.5% to 15.5%. Non-GAAP gross profit margin is projected in the 68.0% to 69.0% range, incorporating an estimated 1.0% impact from tariffs. Non-GAAP operating expense growth is anticipated between 11% and 13%.

Investors will watch procedure volume trends, system placement rates, and the mix between capital sales and leasing arrangements. The expanding installed base of da Vinci and Ion systems supports recurring revenue from instruments and accessories. Tariff developments and their effect on margins remain a key variable through year-end. Upcoming catalysts include updates on digital solutions and new system adoption rates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.